AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2015 by AOP Orphan Pharmaceuticals AG
PharmaEssentia (Co-Sponsor for USA)
Information provided by (Responsible Party):
AOP Orphan Pharmaceuticals AG Identifier:
First received: August 14, 2014
Last updated: December 31, 2015
Last verified: December 2015

Polycythemia Vera (PV) is a disease of bone marrow stem cells that manifests in a drastic increase of red blood cells and frequently also of white blood cells. The "thickening" of the blood in relation with a modified function of the cells has several consequences like increased blood pressure, pruritus of the skin, fatigue, disturbed blood circulation in the brain as well as fingers and toes and an increased risk of arterial and venous thrombosis (thrombosis is the formation of a blood clot in a vessel); like stroke, cardiac infarction, deep vein thrombosis in the legs. In case of a strong increase of platelets there is an additional risk of bleedings. As the disease progresses the size of spleen and liver increased in most cases and the bone marrow shows signs of fibrosis. In some cases of PV a progression at a later time point to a leukemia (increased formation of white blood cells) can occur.

The aim of this study is to show that the study drug AOP2014 (pegylated proline interferon alpha-2b) has the long term efficacy and safety in controlling the disease. Response to the treatment is measured by several blood parameters as well as size of the spleen.

Interferon-alpha has been shown to be effective in controlling the blood parameters by immunologically influencing the blood building cells. This can lead to a suppression of the disease-causing stem cells and help healthy stem cells to proliferate. Through this mechanism it is possible that Interferon-alpha can avoid long-term damaging effects of the disease.

Condition Intervention Phase
Polycythemia Vera
Drug: Pegylated-Proline-interferon alpha-2b
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: An Open-label, Multicenter, Phase IIIb Study Assessing the Long-term Efficacy and Safety of AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.

Resource links provided by NLM:

Further study details as provided by AOP Orphan Pharmaceuticals AG:

Primary Outcome Measures:
  • Hct level of 40 - 42% without phlebotomies. [ Time Frame: 1.5 years ] [ Designated as safety issue: No ]
    Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.

Estimated Enrollment: 130
Study Start Date: November 2014
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Pegylated-Proline-interferon alpha-2b
single arm
Drug: Pegylated-Proline-interferon alpha-2b
Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
Other Name: AOP2014

Detailed Description:
This is a Phase III, single arm, open-label continuation of the PROUD-PV study performed in adults diagnosed with Polycythemia Vera (PV). Only the patients who received AOP2014 in the primary study, PROUD-PV, and completed the end of study visit will be enrolled into this continuation study.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients who completed the 12 months AOP2014 treatment arm of the PROUD-PV study and at the "end-of-treatment visit" (EoT) of the PROUD-PV study who fulfill at least one of the following criteria:

    • normalization of at least two out of three main blood parameters (Hct, PLTs and WBCs) if these parameters were moderately increased (Hct<50%, WBC<20 x 109/L, PLTs<600 x 109/L) at baseline of the PROUD-PV study, OR
    • >35% decrease of at least two out of three main blood parameters (Hct, PLTs and WBCs) if these parameters were massively increased (Hct>50%, WBCs>20 x 109/L, PLTs>600 x 109/L), at baseline of the PROUD-PV study, OR
    • normalization of spleen size, if spleen was enlarged at baseline of the PROUD-PV study, OR
    • otherwise a clear, medically verified benefit from treatment with AOP2014 (e.g. normalization of disease-related micro-vasculatory symptoms, substantial decrease of JAK2 allelic burden).
  2. Signed written ICF.

Exclusion criteria:

Withdrawal criteria, as specified in the PROUD-PV study, which mandate treatment discontinuation:

  1. Non-recovery from the AOP2014 related toxicities to the grade (usually, Grade I) which allows continuation of the treatment.
  2. HADS score of 11 or higher on either or both of the subscales, and /or development or worsening of the clinically significant depression or suicidal thoughts.
  3. Progressive and clinically significant increase of liver enzyme levels despite dose reduction, or if such increase is accompanied by increased bilirubin level, any signs or symptoms of a clinically significant autoimmune disease.
  4. Clinically significant development of a new ophthalmologic disorder, or worsening of a pre-existing one, during the study.
  5. Loss of efficacy of AOP2014 or any comparable situation where no further benefits of treatment continuation are expected by the investigator.

The main efficacy evaluation criterion will be disease response defined as Hct<45% without phlebotomy (at least 3 months since the last phlebotomy), PLTs<400 x 109/L, WBCs<10 x 109/L, and normal spleen size.

The main efficacy endpoint will be the maintenance rate of disease response at assessment visits (every three months).

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02218047

Contact: Oleh Zagrijtschuk, MD +43-1-5037244 - 76
Contact: Michael Zörer, PhD +43-1-5037244 - 46

  Show 54 Study Locations
Sponsors and Collaborators
AOP Orphan Pharmaceuticals AG
PharmaEssentia (Co-Sponsor for USA)
Principal Investigator: Heinz Gisslinger, MD Med Uni Wien
  More Information

Responsible Party: AOP Orphan Pharmaceuticals AG Identifier: NCT02218047     History of Changes
Other Study ID Numbers: CONTINUATION-PV  2014-001357-17 
Study First Received: August 14, 2014
Last Updated: December 31, 2015
Health Authority: Austria: Austrian Medicines and Medical Devices Agency
Bulgaria: Ministry of Health
Czech Republic: State Institute for Drug Control
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Germany: Federal Institute for Drugs and Medical Devices
Hungary: Ministry of Health, Social and Family Affairs
Italy: Ministry of Health
Poland: Ministry of Health
Romania: National Agency for Medicines and Medical Devices
Russia: Ministry of Health of the Russian Federation
Slovakia: State Institute for Drug Control
Spain: Ministry of Health
Ukraine: Ministry of Health

Keywords provided by AOP Orphan Pharmaceuticals AG:
Pegylated-Proline-interferon alpha-2b (AOP2014)
Polycythemia Vera
AOP Orphan
Hematologic Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Peginterferon alfa-2b

Additional relevant MeSH terms:
Polycythemia Vera
Bone Marrow Diseases
Hematologic Diseases
Myeloproliferative Disorders
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on May 01, 2016